Displaying drugs 26 - 50 of 1617 in total
ALMB-0166
ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.
Investigational
Matched Name: … ALMB-0166 …
Matched Description: … ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of …
Matched Description: … ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of …
DAR-0100A
DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Investigational
Matched Name: … DAR-0100A …
Matched Description: … DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for …
Matched Description: … DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for …
PF-03882845
PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.
Investigational
Matched Name: … PF-03882845 …
Matched Description: … PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type …
Matched Description: … PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type …
PF-04958242
PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.
Investigational
Matched Name: … PF-04958242 …
Matched Description: … PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing …
Matched Description: … PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing …
PF-00610355
PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.
Investigational
Matched Name: … PF-00610355 …
Matched Description: … PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease …
Matched Description: … PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease …
PF-04447943
PF-04447943 has been investigated for the treatment of Alzheimer's Disease.
Investigational
Matched Name: … PF-04447943 …
Matched Description: … PF-04447943 has been investigated for the treatment of Alzheimer's Disease. …
Matched Description: … PF-04447943 has been investigated for the treatment of Alzheimer's Disease. …
PF-04691502
PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Investigational
Matched Name: … PF-04691502 …
Matched Description: … PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast …
Matched Description: … PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast …
PF-03635659
Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Investigational
Matched Name: … PF-03635659 …
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Name: … PF-04937319 …
Matched Description: … Of Different Formulations Of PF-04937319 In Healthy Subjects). ... PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
Matched Description: … Of Different Formulations Of PF-04937319 In Healthy Subjects). ... PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
PF-04856884
PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Investigational
Matched Name: … PF-04856884 …
Matched Description: … PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. ... [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination …
Matched Description: … PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. ... [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination …
WVE-003
WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant huntingtin (mHTT) protein.
Investigational
Matched Synonyms: … WVE 003 …
Matched Name: … WVE-003 …
Matched Description: … WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant …
Matched Name: … WVE-003 …
Matched Description: … WVE-003 is an allele-selective antisense oligonucleotide that works to selectively reduce the toxic mutant …
AL-034
AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.
Investigational
Matched Name: … AL-034 …
Matched Description: … AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis …
Matched Description: … AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis …
LTI-03
LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer
Investigational
Matched Name: … LTI-03 …
Matched Description: … LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer …
Matched Description: … LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer …
HH-009
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
Matched Name: … HH-009 …
Matched Description: … HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment …
Matched Description: … HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment …
HSD-016
Hsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016).
Investigational
Matched Name: … HSD-016 …
Matched Description: … (PK), and Pharmacodynamices (PD) of HSD-016). ... Hsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics …
Matched Description: … (PK), and Pharmacodynamices (PD) of HSD-016). ... Hsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics …
AVI-014
AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).
Investigational
Matched Name: … AVI-014 …
Matched Description: … AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF). …
Matched Description: … AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF). …
BCL-005
BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells.
Investigational
Matched Synonyms: … BCL-005 (fused (hybrid) melanoma-dendritic cells) …
Matched Name: … BCL-005 …
Matched Description: … BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells. …
Matched Name: … BCL-005 …
Matched Description: … BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells. …
MT-0169
MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Investigational
Matched Name: … MT-0169 …
Matched Description: … MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to …
Matched Description: … MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to …
GPI-0100
GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response.
The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy.
Investigational
Matched Name: … GPI-0100 …
Matched Description: … GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the ... The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety …
Matched Description: … GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the ... The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety …
GDC-0349
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational
Matched Name: … GDC-0349 …
Matched Description: … GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor. …
Matched Description: … GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor. …
GDC-0425
GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma).
Investigational
Matched Name: … GDC-0425 …
Matched Description: … GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability ... , and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory …
Matched Description: … GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability ... , and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory …
Displaying drugs 26 - 50 of 1617 in total